IMPACT BIOMEDICAL INC. (IBO)
D
Pipeline Grade
Financial Position (from SEC Filings)
$0.0M
Cash & Equivalents
$0.5M
Quarterly Burn Rate
$48M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-12-01 | Phase3 Readout | — |
| 2027-01-30 | Phase3 Readout | — |
| 2027-05-06 | Phase3 Readout | — |
Active Clinical Trials (24)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT04497285 | Real World Study Using Comprehensive Genomic Data on the Next Treatment Decision Making in Metastatic Breast Cancer | OTHER | Active Not Recruiting | 600 |
| NCT05176626 | Long-term Effectiveness of the Antiobesity Medication Phentermine | PHASE4 | Active Not Recruiting | 870 |
| NCT06057181 | Helix Research Network | OTHER | Recruiting | 2,000,000 |
| NCT05893420 | A Rapid Diagnostic of Risk in Hospitalized Patients Using Machine Learning | OTHER | Active Not Recruiting | 30,000 |
| NCT06939673 | Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care | OTHER | Recruiting | 20 |
| NCT07409571 | Palatal Wound Healing After Free Gingival Graft Surgery | OTHER | Recruiting | 55 |
| NCT07397806 | Home-Based Leg Dexterity Trainer for Management of Knee Osteoarthritis | OTHER | Recruiting | 82 |
| NCT06741358 | Using Glialia for Treating Persistent Perceptual Postural Dizziness | PHASE4 | Recruiting | 30 |
| NCT07595549 | A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity | PHASE3 | Recruiting | 954 |
| NCT07351045 | A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without T... | PHASE3 | Recruiting | 2,000 |
| NCT07357415 | A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | PHASE3 | Active Not Recruiting | 600 |
| NCT07438496 | A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | PHASE3 | Recruiting | 600 |
| NCT06075667 | A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Rel... | PHASE3 | Active Not Recruiting | 160 |
| NCT06819878 | A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participan... | PHASE3 | Recruiting | 600 |
| NCT06141473 | Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | PHASE3 | Active Not Recruiting | 1,655 |
| NCT06741969 | Nipocalimab in Moderate to Severe Sjogren's Disease | PHASE3 | Active Not Recruiting | 655 |
| NCT07184996 | An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Activ... | PHASE3 | Recruiting | 980 |
| NCT06662383 | A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity | PHASE3 | Active Not Recruiting | 800 |
| NCT04586023 | Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (R... | PHASE3 | Active Not Recruiting | 751 |
| NCT05031780 | A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP) | PHASE3 | Active Not Recruiting | 286 |
| NCT04273945 | Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension | PHASE3 | Active Not Recruiting | 935 |
| NCT06859268 | A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity | PHASE3 | Active Not Recruiting | 643 |
| NCT06589986 | A Study to Assess the Efficacy and Safety of Afimkibart (Also Known as RO7790121) for Induction and Maintenance Therapy ... | PHASE3 | Active Not Recruiting | 400 |
| NCT06951217 | An Extension Study of Subjects Who Received an Avalyn Inhaled Antifibrotic Agent (SAIL) | PHASE2 | Recruiting | 340 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.